Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

This randomized, open-label, multi-center phase 2 study (NCT03116152) assessed sintilimab, a PD-1 inhibitor, versus chemotherapy in patients with esophageal squamous cell carcinoma after first-line chemotherapy. The primary endpoint was overall survival (OS), while exploratory endpoint was the assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianming, Li, Yi, Fan, Qingxia, Shu, Yongqian, Yang, Lei, Cui, Tongjian, Gu, Kangsheng, Tao, Min, Wang, Xiuwen, Cui, Chengxu, Xu, Nong, Xiao, Juxiang, Gao, Quanli, Liu, Yunpeng, Zhang, Tao, Bai, Yuxian, Li, Wei, Zhang, Yiping, Dai, Guanghai, Ma, Dong, Zhang, Jingdong, Bai, Chunmei, Huang, Yunchao, Liao, Wangjun, Wu, Lin, Chen, Xi, Yang, Yan, Wang, Junye, Ji, Shoujian, Zhou, Hui, Wang, Yan, Ma, Zhuo, Wang, Yanqi, Peng, Bo, Sun, Jiya, Mancao, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844279/
https://www.ncbi.nlm.nih.gov/pubmed/35165274
http://dx.doi.org/10.1038/s41467-022-28408-3

Ejemplares similares

Ejemplares similares